Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Munshi, Nikhil C. | Person |
Why?
|
| Szalat, Raphael | Person |
Why?
|
| Sanchorawala, Vaishali | Person |
Why?
|
| Genomic patterns of progression in smoldering multiple myeloma. | Academic Article |
Why?
|
| Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. | Academic Article |
Why?
|
| The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. | Academic Article |
Why?
|
| 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. | Academic Article |
Why?
|
| A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. | Academic Article |
Why?
|
| A clinically relevant SCID-hu in vivo model of human multiple myeloma. | Academic Article |
Why?
|
| A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. | Academic Article |
Why?
|
| A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. | Academic Article |
Why?
|
| A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. | Academic Article |
Why?
|
| A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. | Academic Article |
Why?
|
| A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. | Academic Article |
Why?
|
| A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. | Academic Article |
Why?
|